Mast Therapeutics, Inc. (MSTX)

[flare9x]

MSTX - Seeing higher volume today

http://finance.yahoo.com/news/mast-therapeutics-reports-fourth-quarter-120000412.html

Key objectives for the remainder of 2013 include:
--Announcing results from the thorough QT/QTc study of MST-188, expected mid-year;
--Soliciting FDA input on our planned phase 2 study in acute limb ischemia, expected in the third quarter;
--Announcing results of nonclinical studies evaluating the physiologic significance of TEG results observed in prior nonclinical studies funded by the Defense Advanced Research Projects Agency (DARPA) Surviving Blood Loss (SBL) program, expected in the second half of the year;
--Initiating a microvascular blood flow sub-study in EPIC, expected in the fourth quarter;
--Initiating a phase 2 clinical proof-of-concept study of MST-188 in acute limb ischemia, expected in late 2013/early 2014;
--Obtaining orphan drug designation for MST-188 for acute limb ischemia;
--Submitting application(s) to request funding from the U.S. government to conduct a phase 2 clinical proof-of-concept study with MST-188 for resuscitation of shock following major trauma; and
--Filling patent applications claiming key aspects of our proprietary manufacturing process.